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Summary
Background Aetiological data for neonatal infections are essential to inform policies and programme strategies, but 
such data are scarce from sub-Saharan Africa. We therefore completed a systematic review and meta-analysis of 
available data from the African continent since 1980, with a focus on regional differences in aetiology and antimicrobial 
resistance (AMR) in the past decade (2008–18).
Methods We included data for microbiologically confirmed invasive bacterial infection including meningitis and 
AMR among neonates in sub-Saharan Africa and assessed the quality of scientific reporting according to Strengthening 
the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI) checklist. We calculated 
pooled proportions for reported bacterial isolates and AMR.
Findings We included 151 studies comprising data from 84 534 neonates from 26 countries, almost all of which were 
hospital-based. Of the 82 studies published between 2008 and 2018, insufficient details were reported regarding most 
STROBE-NI items. Regarding culture positive bacteraemia or sepsis, Staphylococcus aureus, Klebsiella spp, and 
Escherichia coli accounted for 25% (95% CI 21–29), 21% (16–27), and 10% (8–10) respectively. For meningitis, the 
predominant identified causes were group B streptococcus 25% (16–33), Streptococcus pneumoniae 17% (9–6), and 
S aureus 12% (3–25). Resistance to WHO recommended β-lactams was reported in 614 (68%) of 904 cases and 
resistance to aminoglycosides in 317 (27%) of 1176 cases.
Interpretation Hospital-acquired neonatal infections and AMR are a major burden in Africa. More population-based 
neonatal infection studies and improved routine surveillance are needed to improve clinical care, plan health systems 
approaches, and address AMR. Future studies should be reported according to standardised reporting guidelines, 
such as STROBE-NI, to aid comparability and reduce research waste.
Funding Uduak Okomo was supported by a Medical Research Council PhD Studentship
Copyright © 2019 Elsevier Ltd. All rights reserved.
Introduction
An estimated 2·5 million neonatal deaths (deaths in the 
first 28 days after birth) occur each year, representing 
almost half (47%) of all deaths in children younger than 
5 years globally.1 Marked disparities in neonatal mortality 
exist across world regions and countries. The burden is 
highest in sub-Saharan Africa with 39% of all newborn 
deaths and neonatal mortality rate of 27 deaths per 
1000 livebirths.1 Within sub-Saharan Africa, the burden 
of newborn deaths and neonatal mortality has an uneven 
geographical distribution.2 Overall progress towards 
achieving the Sustainable Development Goals’ (SDGs) 
target of 12 deaths per 1000 livebirths or fewer by 
2030 within the region is slow; however, west and central 
Africa have the highest proportion of countries requiring 
major shifts in their mortality reduction to achieve this 
target.3,4
Bacterial infections are a leading cause of global neonatal 
deaths with a high burden of cases in sub-Saharan Africa 
and the risk of mortality from neonatal infections is higher 
than the risk of motality from other neonatal conditions,5 
yet there is a substantial gap in aetiology-specific data from 
the region, with no published trends regarding which 
organisms provide the most risk. Across the region, 
geographical differences in the prevalence of causal 
pathogens might also exist, particularly given the diverse 
prevalence of maternal risk factors (HIV, urinary tract 
infections, and other antenatal infections), neonatal risk 
factors (preterm birth, low birthweight), and varying health 
system contexts, including differential rates of facility 
birth.6 WHO guidelines for the management of suspected 
neonatal infections recommend empirical treatment with 
ampicillin (or benzylpenicillin; cloxacillin if staphylococcal 
infection is suspected) plus gentamicin sulphate as first-
line therapy, with a third-generation cephalosporin as 
second-line therapy for non-responders or patients in 
whom drug-susceptibility testing of bacterial isolates 
indicates resistance to first-line therapy.7 These guidelines 
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do not take into account timing of the infection (early vs 
late) or infants born in hospital and discharged only to 
return to the hospital at a later date with signs of an 
infection. The rise and spread of antimicrobial resistance 
(AMR) threatens treatment of neonatal infection, with the 
potential to erode recent gains in neonatal survival.8 In 
sub-Saharan Africa, resistance to recommended empirical 
therapies among neonatal pathogens has previously been 
reported;9–12 however, regional differences in the use of 
antibiotics and prevalence of resistance has not yet been 
explored.
Neonatal infection aetiology and AMR data are essential 
to inform policies and appropriate management strategies, 
yet remain an unknown in sub-Saharan Africa.13 African 
biomedical research is often published in local rather than 
international journals that are not included in the leading 
international research databases and thus are missed by 
reviews using only these databases.14–19 In 2016, the 
Strengthening the Reporting of Observational Studies 
in Epidemiology for Newborn Infection (STROBE-NI) 
checklist20 was developed to improve scientific reporting 
of neonatal infection studies and facilitate reliable 
comparison of infection data across settings. STROBE-NI 
is an extension of the 2007 22-item STROBE21 checklist 
with 28 additional elements specifically relating to 
neonatal infection. The effect of STROBE-NI on the 
quality of reporting has not yet been assessed. We 
therefore applied STROBE-NI criteria retrospectively in 
our systematic review of serious bacterial neonatal 
infection aetiology and antimicrobial resistance in sub-
Saharan Africa, focusing on regional differences to 
increase the knowledge base and inform research 
priorities in the region.
Methods
Search strategy and selection criteria
In this systematic review and meta-analysis, we searched 
MEDLINE, Embase, Global Health, PubMed, Africa Wide 
Information, and African Index Medicus to identify studies 
from sub-Saharan Africa published from Jan 1, 1980, to 
Research in context
Evidence before this study
Neonatal deaths account for 47% of deaths in children aged 
younger than 5 years globally and infections are one of the 
leading causes of mortality. Linked to the Sustainable 
Development Goals, there has been a strong emphasis on 
promotion of institutional delivery for all births with the aim 
of improving maternal and neonatal outcomes. In 
sub-Saharan Africa, where more than half of the 36 million 
annual births now occur in health facilities, many hospital 
environments have suboptimal hygiene, placing mothers and 
newborns at risk of hospital-acquired infections with 
associated morbidity, mortality, and cost. WHO recommends 
ampicillin (or benzylpenicillin; cloxacillin if staphylococcal 
infection is suspected) plus gentamicin sulphate as treatment 
for serious infections in neonates and infants younger than 
2 months. Antimicrobial resistance is an increasing global 
threat leading to poor treatment outcomes and the potential 
to erode the gains in neonatal survival of the past few 
decades. Cause-specific data for neonatal infections in the 
African continent are scarce, but available data suggest that 
Gram-negative organisms are the predominant cause of 
early-onset sepsis, with a high prevalence of 
extended-spectrum β-lactamase-producing organisms.
Added value of this study
To our knowledge, this is the first systematic review of causes 
of neonatal infection in sub-Saharan Africa, with extensive 
inputs from more than 16 000 initial hits. Our review 
addresses the knowledge gap about causes of invasive 
bacterial infection and antimicrobial resistance, assessing 
regional differences in pathogen dominance and resistance 
patterns. An added strength is that we assessed the quality of 
scientific reporting by applying the Strengthening the 
Reporting of Observational Studies in Epidemiology for 
Newborn Infection (STROBE-NI) checklist.
Implications of all the available evidence
The reporting quality was poor across all studies with many 
items from STROBE-NI not described, thereby making the data 
challenging to combine and interpret. There are few 
population-based studies investigating causes of neonatal 
infection, yet clearly a huge burden of infection among 
neonates in hospitals, including hospital-acquired infections. 
Staphylococcus aureus, Klebsiella spp, and Escherichia coli were 
the leading reported causes of bacteraemia or sepsis, 
supporting the view that inappropriate hygiene during labour, 
delivery, and postnatal care are major contributors in the 
development of neonatal bloodstream infections. For reported 
causes of neonatal meningitis, group B streptococcus and 
Streptococcus pneumoniae dominate and present specific 
opportunities for prevention through maternal immunisation. 
The scarce antimicrobial resistance data suggests resistance to 
WHO recommended first-line antibiotics occurs in more than 
27% of cases and resistance to second-line antibiotics in more 
than 18% of cases.
The use of standardised reporting guidelines such as 
STROBE-NI is strongly recommended for future neonatal 
infection studies. There is also a need for strengthening 
capacity for microbiological diagnosis in local hospitals or 
facilities, and innovations in diagnostics, particularly for 
high-risk pathogens. Geographical variation of pathogens and 
resistance underscore the need for active surveillance and to 
inform region-specific therapeutic guidelines for empirical 
treatment of infections. Infection control policies to combat 
hospital-acquired infections are urgently needed.
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June 6, 2018 (date of last search), which reported aetiology 
of invasive bacterial infections (bacteraemia, sepsis, 
septicaemia, or meningitis), and specified neonatal data 
(or clearly delineated neonatal data from other age groups). 
Each database was searched using terms identified from 
Medical Subject Headings (MeSH) related to age, clinical 
infectious syndromes, and geographical descriptors, as 
well as terms used for systematic reviews on similar topics 
in various combinations as follows: “neonatal”, “newborn”, 
“infant”, “sepsis”, “infection”, “pathogen”, “bacteria”, 
“virus”, “aetiology”, “Africa”, “sub-Saharan” (appendix 
pp 3–5). There were no language restrictions on the search.
Studies were excluded if they presented data aggregated 
with regions beyond sub-Saharan Africa; reported on a 
single pathogen (because this might lead to a biased 
estimate of the significance of that pathogen), solely high-
risk subpopulations (such as very low birthweight, 
extremely premature, or having encephalopathy), or only 
newborns with potentially confounding comorbidities 
(malaria, tetanus, syphilis, tuberculosis, or HIV); contained 
erroneous, incomplete, or internally inconsistent data; or 
assessed the diagnostic accuracy of any test using only 
positive samples and not in the clinical context of suspected 
neonatal infection. Preterm and low birthweight infants 
are a unique and high-risk group for many morbidities 
including hospital-acquired infections. The prevalence of 
HIV infection also varies across sub-Saharan Africa and 
influences the risk of neonatal group B streptococcus 
sepsis in high-prevalence settings but not to other 
pathogens. Including studies that reported only these 
high-risk groups could possibly bias the significance of the 
aetiology results.
Abstracts and titles were compiled into Endnote 
(Thomson Reuters) and duplicates were removed, and 
then reviewed individually by two investigators (UO 
and ENKA) to identify potentially eligible articles. 
All identified articles were retrieved in full text 
(where available) and their reference lists were again 
independently assessed by both reviewers through 
PubMed and African Journals Online to obtain relevant 
abstracts as needed. Articles identified by this process as 
potentially eligible for inclusion were also retrieved as 
full text. French articles were read by both UO and 
ENKA. We made every attempt to contact the authors for 
copies of full text articles not available in the public 
domain. Where the full text could not be retrieved but 
enough detail was presented in the abstract, we used data 
from the abstract. We also included grey literature (theses 
and dissertations). Disagreements over inclusion were 
resolved by consensus. Studies published between 
1980 and 2007 were not included in the meta-analysis.
Data analysis
Information was independently extracted from selected 
articles by two investigators (UO and ENKA) and entered 
into a spreadsheet, including country and region of 
sub-Saharan Africa (central, eastern, southern or 
west Africa as defined by the African Union),22 study year, 
publication year, location, setting, case ascertainment, 
and microbiological techniques, number of neonates 
investigated, sample volume, number of cultures carried 
out and the proportion that were positive, number of 
invasive bacterial isolates and, when available, results of 
antimicrobial susceptibility testing. Previous reviews 
excluded coagulase-negative staphylococci (CoNS), which 
Figure 1: Study selection
16 059 records identified in literature search
 6669 from Africa-Wide Information
 24 from African Index Medicus
 684 from Embase
 423 from Global Health
 414 from MEDLINE
 7845 from PubMed
12 120 records after duplicates removed
193 records after screening of titles and abstracts
170 full-text articles assessed for eligibility
151 studies included in final review*
26 additional studies identified via reference
 list searches and grey literature review 
69 studies published between 1980–2007 82 studies published between 2008–18
3939 duplicate records removed
23 records excluded because no full text available
11 927 records excluded during screening of titles and 
 abstracts because of non-relevance
46 full-text articles excluded
 13 aetiology data not disaggregated by
  participant age, sample type, or study location
  (data from regions beyond sub-Saharan 
  African included)
 11 aetiology data not reported
 8 neonatal data not analysed separately to 
  paediatric data
 8 data published elsewhere
 3 neonates not included in study population
 1 had inconsistent results
 1 had incomplete data
 1 post-mortem blood cultures from dying
  babies
81 observational
      studies
1 randomised 
   controlled trial
See Online for appendix
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are potentially pathogenic in very preterm neonates who 
are in intensive care with ventilator support and 
in-dwelling devices that are not frequently used in many 
sub-Saharan African settings.23,24 We therefore excluded 
data for CoNS from summary tables. Inconsistencies 
between investigators in data extraction were resolved by 
further review of the original papers.
Data reporting completeness was assessed by applying 
the STROBE-NI checklist (appendix pp 6–8) for 
studies published after 2007. Each study was assessed 
independently by two investigators (UO and ENKA), and 
item reporting classified as “not reported or unclear”, 
“some information mentioned but insufficient”, or “clear 
and detailed information provided”.
To analyse the aetiological data, studies were arranged 
into two groups according to the year of publication: 
1980–2007 and 2008–18. Data on invasive bacterial 
infections (bacteraemia or sepsis and meningitis) were 
collated for each period. However, to assess current 
aetiology and antimicrobial resistance, analysis was 
restricted to studies published between 2008 and 2018. 
We calculated pooled proportions per pathogen for 
bacteraemia and meningitis using random effects meta-
analysis of binominal data, applying the Freeman-Tukey 
Double Arcsine Transformation to stabilise variances.25,26 
We used random effects models to allow for interstudy 
heterogeneity.27 We also did post-hoc subgroup analyses 
by country in each region, and other study characteristics 
(by data collection, data source, study area, study design, 
type of health-care facility, blood culture method, and 
geographical area) in countries with more than ten 
studies and high heterogeneity. We used Stata (version 13) 
for all statistical analyses.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Our systematic review identified 16 059 records (figure 1), 
from which we identified 150 eligible studies (including 
nine theses and dissertations28–36) meeting our inclusion 
criteria. For 23 potentially eligible studies, we were 
unable to obtain the full text (appendix p 9). 75 (50%) of 
150 included studies were identified only in African 
databases. One study37 reported data from two west 
African countries and was counted as two separate 
studies, resulting in a total of 151 included studies, for 
which study characteristics can be found in the 
appendix (pp 10–28). 11 studies29,32,37–45 were in French and 
the rest were in English; no studies in Portuguese or 
any African language were identified. The total study 
population included 84 534 neonates from 26 sub-
Saharan African nations (figure 2), a third of which were 
from Nigeria (49 [33%] of 151).
132 studies investigated only neonatal patient 
populations, and from the other 19 studies40,45–62 we 
extracted neonatal data from mixed age-group datasets. 
All studies were hospital-based except for one community 
(home-based surveillance) study from Madagascar.63 
Hospital-based studies were mostly tertiary referral 
facilities (university or large national hospitals), and only 
23 from district or secondary referral hospitals.34,48,51,54,59–62,64–78 
139 studies were in urban settings whereas others 
reported data from predominantly rural populations: five 
studies from Kenya,54,61,64,65,68 three from Mozambique,59,72,73 
two from Nigeria,79,80 and one from Cameroon.77 88 studies 
involved prospective data collection, 61 were retrospective 
reviews (26 laboratory-based surveillance of aetiological 
data), and two studies had both retrospective and 
prospective components. There was one randomised 
trial,28 one before-and-after study,81 three case-control 
studies,42,78,82 six observational cohort studies,38,48,63,83–85 and 
the remaining 139 studies were cross-sectional designs.
69 studies were published between 1980 and 2007, 
with the remaining 82 studies published between 
Figure 2: Geographical representation of included studies and neonatal mortality
Study locations and variation between in the number of studies per country reporting microbiological data on 
neonatal invasive bacterial infections (bacteraemia or sepsis, or meningitis) in sub-Saharan Africa between 
1980 and 2018.
>10 studies
6–10 studies
1–5 studies
No data
Not applicable
1
9
8
106
4
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7
3
Ten countries with highest annual
neonatal death numbers (2017)
Nigeria (247 000)
Ethiopia (90 000)
Tanzania (46 000)
Uganda (37 000)
Kenya (34 000)
Côte d'Ivoire (32 000)
Mozambique (30 000)
Mali (27 000)
Niger (26 000)
Ghana (24 000)
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2008 and 2018. Figure 3 summarises the completeness 
of reporting from 81 observational studies (excluding 
1 randomised trial) published after 2007, as outlined 
in the STROBE-NI checklist. Case ascertainment by 
physician diagnosis was reported in 44 (54%) of 
81 observational studies, 26 of which documented the 
individual clinical signs used for the diagnosis of 
neonatal sepsis or meningitis. Only seven studies36,63,74,86–89 
reported using the WHO/IMCI clinical algorithm, 
two studies90,91 used the French National Agency for 
Accreditation and Health clinical diagnostic criteria,92 
and one Ugandan study93 reported using criteria adopted 
from International Paediatric Sepsis Consensus94 
and Indian Academy of Paediatrics.95 30 (37%) of 
these observational studies reported microbiological or 
laboratory criteria for diagnosis of neonatal infection 
syndromes (sepsis or meningitis), and 56 studies (69%) 
described micro biological sample type and sampling 
strategy (clinical indication vs routine sampling) as well 
as number of neonates sampled. 60 studies reported only 
blood culture data, 11 studies reported only cerebrospinal 
fluid data, and ten studies reported both blood and 
cerebrospinal fluid data of which only eight reported 
disaggregated data.
Of 70 studies that reported blood culture data, 13 were 
retrospective reviews of laboratory data and did not report 
the number of culture samples per infant. Nine 
studies88,89,93,96–101 reported submission of two blood 
cultures from each neonate, whereas all other studies 
reported collection of a single sample. Across these 
studies, a total of 31 564 blood cultures were collected of 
which 7856 (25%) were positive for a bacterial pathogen 
(appendix p 29). Few studies (15 of 70; 21%) reported the 
timing of sampling in relation to antimicrobial 
administration. Blood volume for culture was reported 
by 36 (51%) studies, ranging from 0·4–5 mL. 62 (80%) of 
70 studies included data on the number (and proportion) 
of blood samples cultured, number (and proportion) that 
were positive, and the number of pathogens isolated. 
Although 53 (76%) of these studies reporting blood 
Figure 3: Assessment of reporting completeness and quality of included studies
A heat map showing grading of reporting completeness and quality for selected items according to Strengthening the Reporting of Observational Studies in 
Epidemiology for Newborn Infection (STROBE-NI) criteria from 81 observational studies on neonatal infections in sub-Saharan Africa.
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culture data also described the methods used, the culture 
media and methods of identification of organisms varied 
between studies. More studies (n=28) used manual blood 
culture methods than automated techniques (n=24; 
appendix p 29), and one study reported using both. 
Between eight and 44% of cultures were positive among 
studies using automated techniques, and 14–87% among 
studies using manual methods.
Of 19 studies that reported disaggregated cerebrospinal 
fluid culture data, only 1131,48,63,68,73,89,90,102–105 reported on both 
the number of lumbar punctures carried out and the 
number of these that were positive. Across these studies, 
1738 lumbar punctures were reported, of which 
135 (8%) were positive, with positivity ranging from 0 to 
100% (appendix p 30).
41 (51%) studies clearly described the antimicrobial 
susceptibility tests used, the most widely reported of 
which was the Kirby-Bauer disc diffusion method. 
Only few studies reported use of Etest72,73,106,107 or 
microdilution59 on all or some isolates. Several established 
guidelines for resistance interpretation were referenced: 
Clinical and Laboratory Standards Institute (CLSI; 
36 stu dies),24,31,36,56,59,63,70,72,73,84,86–88,93,96,99,103,106,108–125 EUCAST,107 British 
Society for Antimicrobial Therapy,60,61,71,97 and French Society 
of Microbiology.91
Only 12 (15%) of 81 observational studies provided 
context by describing the pathway of neonatal presentation. 
Most described the neonatal population according to place 
of birth as either “inborn” or “outborn”, referring to being 
born in a particular facility rather than at home or a 
different health facility, and only one study34 mentioned all 
neonatal presentations to the neonatal unit. Important 
neonatal characteristics such as gestational age and 
birthweight were each reported by fewer than 38 (47%) of 
the studies, most of which presented data in discrete 
categories with summary statistics (medians and ranges). 
Data on comorbidities (eg, encephalopathy) and feeding 
were rarely reported, and only six of the included studies 
reported neonatal HIV exposure or testing.
71 (88%) of 81 studies did not report the level or type of 
neonatal care (appendix p 32), with the context poorly 
described across all studies, regarding basic neonatal 
care (resuscitation and breastfeeding), intensive neonatal 
care (oxygen supplementation, invasive and non-invasive 
respiratory support, and indwelling devices), nurse-to-
patient ratio, and non-microbiological invest igations. 
Only 25 (31%) of 81 studies reported the antimicrobial 
guidelines used for empirical management of neonatal 
sepsis (appendix p 31).
Description of microbiological laboratory context was 
also poor across all studies, regarding facilities, sample 
types, and capacity for conventional or molecular 
microbiology. Most of the studies reported selected 
pathogens and did not provide full data of all organisms. 
Only one South African study126 and two Nigerian 
studies88,89 stated criteria used to identify the clinical 
significance of detected organisms. Only 13 (16%) of 
81 studies listed pathogens excluded as contaminants. 
Although often reported as contaminants, several 
studies reported CoNS,24,34,38,55,71,74,86–89,96,98,103,106,109,111–113,115–118,120,126–132 
viridians streptococci,61,85 Staphylococcus epider- 
midis,84,99,125,133,134 Bacillus spp,106,130 and Micrococcus spp122 as 
neonatal pathogens. However, among the studies that 
reported CoNS as a pathogen, few provided a rationale for 
identifying the clinical significance of the 
infection.24,36,122,131,132,135 Four studies36,60,107,121 cited laboratory 
quality control measures, and only one study107 sent 
samples to an external laboratory for confirmation.
1980–2007 2008–18 
Number of 
isolates
Proportion (95% CI) Number of 
isolates
Proportion (95% CI)
Bacteraemia or sepsis
Gram-positive
Staphylococcus aureus 912 0·25 (0·19–0·31) 2080 0·25 (0·21–0·29)
Streptococcus pyogenes 75 0·04 (0·02–0·08) 117 0·04 (0·02–0·07)
Group B streptococci 213 0·07 (0·03–0·12) 342 0·06 (0·03–0·10)
Group D streptococci or 
enterococcus
139 0·05 (0·03–0·07) 449 0·05 (0·04–0·07)
Streptococcus pneumoniae 72 0·04 (0·02–0·08) 114 0·02 (0·01–0·04)
Viridians streptococci 7 0·01 (0–0·05) 71 0·03 (0·01–0·05)
Other Streptococcus species 63 0·03 (0·01–0·05) 209 0·05 (0·03–0·07)
Other or unspecified 
Gram-positives
86 0·04 (0·01–0·08) 155 0·06 (0·03–0·09)
Gram-negative
Klebsiella species 644 0·15 (0·11–0·20) 1730 0·21 (0·16–0·27)
Escherichia coli 377 0·10 (0·08–0·13) 856 0·10 (0·08–0·13)
Pseudomonas species 146 0·04 (0·02–0·05) 189 0·03 (0·02–0·04)
Enterobacter species 270 0·08 (0·03–0·13) 263 0·04 (0·03–0·05)
Serratia species 0 ·· 129 0·03 (0·01–0·07)
Proteus species 54 0·02 (0·01–0·04) 126 0·03 (0·02–0·04)
Salmonella species 162 0·03 (0·02–0·05) 176 0·04 (0·02–0·06)
Citrobacter species 61 0·04 (0·01–0·07) 122 0·02 (0·02–0·04)
Haemophilus influenzae 11 0·01 (0–0·02) 10 0·01 (0–0·03)
Neisseria meningitidis 0 ·· 17 0·03 (0–0·08)
Acinetobacter species 94 0·05 (0·02–0·07) 299 0·05 (0·03–0·07)
Other or unspecified 
Gram-negatives
522 0·20 (0·14–0·27) 508 0·10 (0·06–0·14)
Other pathogens 14 0·05 (0·02–0·07) 9 0·02 (0·01–0·04)
Meningitis
Gram-positive
S aureus 77 0·18 (0·07–0·32) 92 0·12 (0·03–0·25)
S pyogenes 10 0·01 (0–0·03) 8 0·07 (0·03–0·12)
Group B streptococcus 297 0·26 (0·18–0·35) 416 0·24 (0·16–0·33)
Group D streptococcus or 
enterococcus
8 0·03 (0–0·07) 68 0·03 (0·01–0·06)
S pneumoniae 210 0·15 (0·11–0·21) 157 0·17 (0·09–0·26)
Viridians streptococci 0 ·· 13 0·01 (0–0·03)
Other Streptococcus species 36 0·06 (0·02–0·11) 37 0·03 (0·02–0·04)
Other or unspecified 
Gram-positives
23 0·04 (0·02–0·07) 12 0 (0–0·01)
(Table 1 continues on the next page)
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Between 1980 and 2007, Staphylococcus aureus 
infections accounted for 25% (95% CI 19–31) of all 
reported cases of neonatal bacteraemia or sepsis, with 
Klebsiella spp (mostly Klebsiella pneumoniae) accounting 
for 15% (11–20), and Escherichia coli 10% (8–13; table 1). 
These three pathogens, plus unidentified Gram-negative 
organisms, accounted for more than two-thirds of all 
reported causes of bacteraemia or sepsis. We observed 
similar distributions between 2008 and 2018, with 
S aureus accounting for 25% of cases (95% CI 21–29), 
Klebsiella spp accounting for 21% (16–27), and E coli 
accounting for 10% (8–10; table 1).
Only one paper136 delineated hospital-acquired and 
community-acquired pathogens, with a similar prevalence 
of Klebsiella spp among neonates with hospital-acquired 
infection (31% [10/32] vs 17% [8/48]; p=0·126) and a 
similar prevalence of S aureus among those with 
community-acquired infection (17% [8/48] vs 13% [4/32]; 
p=0·609). Three studies61,63,72 specifically examined 
community-acquired infections, and two studies24,81 
reported only hospital-acquired infections; the remaining 
studies did not analyse pathogens by place of acquisition. 
We were unable to carry out post-hoc analysis of 
differences in aetiology by gestational age, birth weight, 
and HIV status because of the poor reporting of these 
data across the studies.
Table 2 shows the regional distribution of reported 
causes of neonatal bacteraemia or sepsis. In central and 
southern Africa, Klebsiella spp was the predominant 
isolate representing 34% (95% CI 15–56) of bacteraemic 
infections in central Africa and 25% (10–41) in southern 
Africa; whereas S aureus was the most common isolate 
accounting for 20% (14–28) of cases in east Africa and 
32% (25–39) in west Africa (table 2). We observed both 
intraregional and inter-regional heterogeneity in all 
our meta-analyses (I² range 56–98%), both overall 
and in subgroups defined by region (figure 3 and 
appendix pp 33–53). We completed further sensitivity 
analyses stratifying for important study characteristics, 
which showed significant differences in the prevalence 
of S aureus bacteraemia between countries in each region 
(appendix pp 76–79). 1020 (80%) of 1282 S aureus isolates 
in west Africa were reported from Nigerian studies. Of 
these, the prevalence of S aureus bacteraemia was higher 
among retrospective studies compared with prospective 
studies (47% vs 30%, p=0·043), and among studies 
reported from tertiary health-care facilities compared 
with those from secondary facilities and (36% vs 23%; 
p=0·020; appendix pp 80–86).
Table 1 also shows pooled pathogen prevalence 
associated with neonatal meningitis by time period. 
Group B streptococcus (26%, 95% CI 18–35) was the 
most commonly reported cause of meningitis between 
1980 and 2007, followed by S aureus (18%, 7–32), 
S pneumoniae (15%, 11–21), Klebsiella spp (15%, 9–21), 
and E coli (15%, 10–20). Between 2008 and 2018, group B 
streptococcus, S pneumoniae, and S aureus remained the 
major reported causes of neonatal meningitis (table 1). 
Group B streptococcus was predominant in east Africa 
(19%, 11–28) and southern Africa (31%, 21–41), although 
most of the data were from South Africa (table 2). We 
observed variable heterogeneity (0–87%) in the cause of 
neonatal meningitis between regions (figure 4 and 
appendix pp 54–75).
63 (78%) of 81 included studies reported in-vitro 
antibiotic susceptibility data but only 29 studies 
specified individual pathogens and reported isolates 
numbers. No study reported minimum inhibitory 
concentrations to the antibiotics reported, making 
it difficult to assess intermediate or decreased 
susceptibility. Table 3 presents findings for the most 
prevalent isolates.
22 studies36,63,74,79,84,86,88,91,93,97,98,106,112,113,118,123–127,132,135 reported 
resistance among Klebsiella spp (predominantly 
K pneumoniae, with few cases of Klebsiella oxytoca), 
documenting a non-susceptibility to gentamicin of 
66% (95% CI 47–83), ceftriaxone of 49% (28–71), and 
cefotaxime of 78% (55–95). Reported resistance to 
amikacin, an alternative to gentamicin, was low (14%, 
7–23).63,113,124–126,132,135 High frequencies of extended spectrum 
β-lactamase (ESBL)-producing K pneumoniae  were 
reported from South Africa,24,126,131,132 Tanzania 
(49%; 24/50),86 and Botswana (60%; 16/27).135 In one 
South African study,126 resistance to piperacillin-
tazobactam, was higher among ESBL-producing 
K pneumoniae isolates (90%; 9/10) than in the non-ESBL 
producing isolates (43%; 3/7). Non-susceptibility to 
carbapenems was reported in at least one country in each 
1980–2007 2008–18
Number of 
isolates
Proportion (95% CI) Number of 
isolates
Proportion (95% CI)
(Continued from previous page)
Gram-negative
Klebsiella species 150 0·15 (0·09–0·21) 39 0·10 (0·04–0·18)
E coli 170 0·15 (0·10–0·20) 45 0·11 (0·06–0·18)
Pseudomonas species 21 0·04 (0·02–0·08) 6 0·03 (0–0·08)
Enterobacter species 29 0·07 (0·03–0·13) 15 0·06 (0·02–0·11)
Serratia species 11 0·05 (0·02–0·10) 3 0·08 (0·01–0·20)
Proteus species 19 0·03 (0·01–0·05) 2 0·01 (0–0·06)
Salmonella species 68 0·06 (0·03–0·10) 19 0·08 (0·05–0·13)
Citrobacter species 12 0·07 (0·02–0·14) 3 0·04 (0–0·11)
H influenzae 36 0·04 (0·02–0·07) 10 0·01 (0–0·04)
N meningitidis 25 0·02 (0–0·08) 20 0·04 (0–0·10)
Acinetobacter species 9 0·04 (0·01–0·08) 9 0·10 (0·04–0·17)
Other or unspecified Gram-
negatives
114 0·11 (0·07–0·15) 394 0·12 (0·02–0·25)
Other pathogens 80 0·24 (0·17–0·32) 11 0·01 (0–0·02)
Bacteraemia or sepsis pathogens represent data pooled across 43 studies in 1980–2007, and 71 studies in 2008–18. 
Meningitis pathogens represent data pooled across 38 studies in 1980–2007, and 19 studies in 2008–18.
Table 1: Pooled pathogen prevalence estimates of neonatal infections in sub-Saharan Africa, by period of 
publication
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Central Africa Eastern Africa Southern Africa West Africa All regions 
n Proportion 
(95% CI)
n Proportion 
(95% CI)
n Proportion 
(95% CI)
n Proportion (95% CI) n Proportion (95% CI)
Bacteraemia or sepsis
All Gram positives 22 ·· 546 ·· 1306 ·· 1663 ·· 3537 ··
Staphylococcus aureus 13 0·26 (0·14–0·40) 296 0·20 (0·14–0·28) 489 0·12 (0·07–0·19) 1282 0·32 (0·25–0·39) 2080 0·25 (0·21–0·29)
Streptococcus pyogenes 2 0·04 (0–0·11) 46 0·06 (0·05–0·08) 50 0·04 (003–0·05) 19 0·03 (0–0·09) 117 0·04 (0·02–0·07)
Group B streptococci 2 0·08 (0·02–0·24) 35 0·02 (0–0·06) 290 0·10 (0·05–0·17) 15 0·05 (0–0·27) 342 0·06 (0·03–0·10)
Group D streptococci 
or enterococcus
1 0·04 (0·01–0·19) 71 0·06 (0·05–0·08) 242 0·08 (0·06–0·10) 135 0·04 (0·02–0·06) 449 0·05 (0·04–0·07)
Streptococcus 
pneumoniae
0 ·· 31 0·03 (0·01–0·06) 59 0·04 (0·03–0·05) 24 0·01 (0–0·03) 114 0·02 (0·01–0·04)
Viridians streptococci 0 ·· 15 0·04 (0·02–0·06) 17 0·06 (0·03–0·09) 39 0 (0–0·01) 71 0·03 (0·01–0·05)
Other Streptococcus 
species or unspecified
4 0·07 (0·01–0·16) 22 0·03 (0·01–0·06) 72 0·04 (0–0·11) 111 0·06 (0·03–0·10) 209 0·05 (0·03–0·07)
Other or unspecified 
Gram positives
·· ·· 30 0·14 (0–0·43) 87 0·03 (0–0·07) 38 0·07 (0·01–0·18) 155 0·06 (0·03–0·09)
All Gram negatives 68 ·· 766 ·· 1603 ·· 1988 ·· 4425 ··
Klebsiella species 38 0·34 (0·15–0·56) 299 0·19 (0·13–0·25) 732 0·25 (0·10–0·41) 641 0·21 (0·14–0·28) 1730 0·21 (0·16–0·27)
Escherichia coli 17 0·17 (0·07–0·29) 146 0·10 (0·07–0·14) 241 0·08 (0·06–0·10) 452 0·11 (0·06–0·16) 856 0·10 (0·08–0·13)
Pseudomonas species 0 ·· 15 0·01 (0·01–0·03) 42 0·01 (0·01–0·02) 132 0·05 (0·03–0·06) 189 0·03 (0·02–0·04)
Enterobacter species 4 0·07 (0·01–0 ·06) 88 0·07 (0·03–0·12) 79 0·02 (0·01–0 ·04) 92 0·03 (0·02–0·05) 263 0·04 (0·03–0·05)
Serratia species 0 ·· 26 0·04 (0·01–0·09) 86 0·04 (0–0·13) 17 0·02 (0–0·06) 129 0·03 (0·01–0·07)
Proteus species 1 0·04 (0·01–0 ·09) 9 0·02 (0·01–0·03) 3 0·01 (0–0·04) 113 0·04 (0·02–0·05) 126 0·03 (0·02–0·04)
Salmonella species 0 ·· 29 0·04 (0·02–0·06) 98 0·07 (0·04–0·11) 49 0·03 (0·01–0·05) 176 0·04 (0·02–0·06)
Citrobacter species 1 0·04 (0·01–0·19) 11 0·07 (0·03–0·12) 23 0·02 (0·01–0·03) 87 0·03 (0·02–0·04) 122 0·02 (0·02–0·04)
Haemophilus influenzae 0 ·· 4 0 (0–0·01) 2 0 (0–0·01) 4 0·04 (0·01–0·09) 10 0·01 (0–0·03)
Neisseria meningitidis 0 ·· 12 0·01 (0–0·02) 3 0·01 (0–0·02) 2 0·04 (0·01–0·13) 17 0·03 (0–0·08)
Acinetobacter species 6 0·11 (0·03–0·21) 54 0·05 (0·01–0 ·09) 156 0·07 (0·03–0·11) 83 0·02 (0·02–0·03) 299 0·05 (0·03–0·07)
Other or unspecified 
Gram negatives
1 0·04 (0·01–0·19) 73 0·09 (0·03–0 ·17) 118 0·04 (0·02–0·06) 316 0·14 (0·07–0·23) 508 0·10 (0·06–0·14)
Other pathogens 0 ·· 9 0·02 (0·01–0 ·04) 0 ·· 0 ·· 9 0·02 (0·01–0 ·04)
Meningitis
All Gram positives 1 ·· 67 ·· 697 ·· 40 ·· 805 ··
S aureus 0 ·· 4 0·05 (0·01–0·12) 71 0·02 (0·01–0·03) 17 0·29 (0·17–0·42) 92 0·12 (0·03–0·25)
S pyogenes 0 ·· 8 0·07 (0·03–0·12) 0 ·· 0 ·· 8 0·07 (0·03–0·12)
Group B streptococci 1 0·50 (0·09–0·91) 16 0·19 (0·11–0·28) 394 0·31 (0·21–0·41) 5 0·21 (0·01–0·52) 416 0·24 (0·16–0·33)
Group D streptococci 
or enterococcus
0 ·· 3 0·03 (0–0·08) 60 0·05 (0·03–0·06) 5 0·08 (0–0·25) 68 0·03 (0·01–0·06)
S pneumoniae 0 ·· 31 0·18 (0·08–0·30) 113 0·12 (0·04–0·24) 13 0·27 (0–0·70) 157 0·17 (0·09–0·26)
Viridians streptococci 0 ·· 2 0·02 (0–0·07) 11 0·01 (0·01–0·02) 0 ·· 13 0·01 (0–0·03)
Other Streptococcus 
species or unspecified
0 ·· 2 0·04 (0·01–0·12) 35 0·03 (0·02–0·04) 0 ·· 37 0·03 (0·02–0·04)
Other or unspecified 
Gram positives
0 ·· 1 0·05 (0·01–0·24) 13 0·01 (0·01–0·02) 0 ·· 14 0 (0–0·01)
All Gram negatives 3 ·· 83 ·· 431 ·· 48 ·· 565 ··
Klebsiella species 1 0·50 (0·09–0·91) 10 0·07 (0·03–0·12) 18 0·22 (0·02–0·51) 10 0·10 (0·03–0·19) 39 0·10 (0·04–0·18)
E coli 1 0·50 (0·09–0·91) 16 0·11 (0·06–0·17) 8 0·06 (0·02–0·13) 20 0·22 (0·08–0·38) 45 0·11 (0·06–0·18)
Pseudomonas species 0 ·· 2 0·06 (0–0·20) 1 0·02 (0–0·09) 3 0·03 (0–0·10) 6 0·03 (0–0·08)
Enterobacter species 1 0·50 (0·09–0·91) 9 0·10 (0·04–0·18) 4 0·07 (0·03–0·16) 1 0·07 (0·01–0·30) 15 0·06 (0·02–0·11)
Serratia species 0 ·· 0 ·· 3 0·08 (0·03–0·22) 0 ·· 3 0·08 (0·01–0·20)
Proteus species 0 ·· 2 0·01 (0–0·06) 0 ·· 0 ·· 2 0·01 (0–0·06)
Salmonella species 0 ·· 10 0·08 (0·03–0·13) 7 0·12 (0·06–0·22) 2 0·06 (0–0·19) 19 0·08 (0·05–0·13)
Citrobacter species 0 ·· 1 0·11 (0·02–0·43) 0 ·· 2 0·04 (0·01–0·13) 3 0·04 (0–0·11)
(Table 2 continues on next page)
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region,63,86,88,91,106,125,126,132 with low resistance rates 
(4%, 95% CI 1–10).
Pooled prevalence of non-susceptibility of E coli 
isolates to ampicillin63,74,79,84,86,88,98,106,112,113,118,124,125,127,132,135 was 
89% (95% CI 77–97) and was 47% (25–69) to 
gentamicin.63,74,79,84,86,88,91,97,98,106,126,127,113,118,132,135,123–125 A third of E coli 
isolates were resistant to ceftriaxone.74,79,84,86,88,97,98,106,112,113,118,122,133 
The reported prevalence of ESBL-producing E coli isolates 
ranged from 12% (7/58) in South Africa24 to 46% (10/22) in 
Tanzania.86 Resistance to piperacillin-tazobactam was also 
low (7%, 0–27).63,125,132,135 Only two studies reported 
carbapenem resistant isolates: one each from Tanzania86 
and South Africa.126
For S aureus infection, WHO recommends first-line 
treatment with cloxacillin, which has a pooled resistance 
of 40% (95% CI 8–79),79,84,93,97,98,123,124,127 and gentamicin, 
for which the pooled resistance was 27% 
(14–41).63,79,84,88,93,97,98,106,111,113,118,123,124,127,135 Meticillin resis tance was 
reported by eight studies,24,86,112,118,121,126,131,137 with 50% (30–70) 
of isolates non-susceptible. Resistance to cefoxitin, the 
recommended antibiotic to identify meticillin-resistant 
S aureus strains (MRSA) when using the disk diffusion 
method,138 was reported in 27% (13/49) of isolates in an 
Ethiopian study,113 and 26% (6/23) of isolates in a Nigerian 
study.88 None of the two studies that analysed susceptibility 
patterns of group B streptococcus infections documented 
non-susceptibility to any antibiotic.124,135
Discussion
To our knowledge, this study is the largest systematic 
review of neonatal infection aetiology and AMR from sub-
Saharan Africa, and a strength of the study is the 
assessment of reporting quality using STROBE-NI.20 The 
inclusion of African regional research databases in our 
search strategy resulted in the identification of 75 more 
relevant studies than would have been identified only 
through the use of usual major databases, although central 
Africa is still poorly represented. Our review represents a 
notable increase in studies from Africa compared with 
previous reviews in which the number of included sub-
Saharan African studies ranged from seven to 23.9,14–19 We 
highlight the variability in recording and reporting, across 
and within manuscript sections which impede 
comparability of results and utility of available data. No 
single STROBE-NI item was adequately addressed across 
all manuscripts, and although this could be improved with 
wider use of STROBE-NI guidelines, this review could 
therefore not distinguish between infections that were 
maternally, community, or hospital acquired.
In many sub-Saharan African hospitals, sick newborn 
children do not routinely undergo microbiological 
investigations.133,139 Considering that the annual need-to-
treat population for possible serious bacterial infection 
in sub-Saharan Africa is 2·6 million, with around ten 
cases of possible severe bacterial infection diagnosed for 
each associated neonatal death,140 the 31 874 blood 
cultures and 1742 lumbar punctures reported in the 
studies identified in this review (of which 25% and 
8% respectively were culture-positive) revealed the 
paucity of published data for such a large population at 
risk. A published audit of almost 5000 neonates admitted 
in the main hospital in The Gambia found that 
94% received antibiotics, but only 26 neonates had a 
blood culture sample taken (of which six had a result), 
and even fewer had a lumbar puncture result.139 A 
lumbar puncture is part of the diagnostic work-up for all 
sick newborn children with possible serious bacterial 
infection to identify meningitis and give the most 
appropriate antibiotic for the correct time period. 
Routine investigations for neonates such as blood 
cultures and lumbar punctures need to be instated as 
standard of care, but requires investments in clinical 
care workers, commodities, and laboratories.
Nearly a decade ago, in a review of studies published 
between 1980 and 2007, Zaidi and colleagues15 reported 
group B streptococcus, S pneumoniae, Salmonella spp, 
and S aureus, as dominant pathogens associated with 
invasive bacterial infection in African neonates. However, 
this study did not distinguish between causes of 
bacteraemia or sepsis and meningitis, or assess sub-
Central Africa Eastern Africa Southern Africa West Africa All regions 
n Proportion 
(95% CI)
n Proportion 
(95% CI)
n Proportion 
(95% CI)
n Proportion (95% CI) n Proportion (95% CI)
(Continued from previous page)
H influenzae 0 ·· 2 0·02 (0–0·07) 6 0 (0–0·01) 2 0·04 (0·01–0·13) 10 0·01 (0–0·04)
N meningitidis 0 ·· 7 0·04 (0–0·13) 9 0·02 (0–0·14) 4 0·04 (0–0·11) 20 0·04 (0–0·10)
Acinetobacter species 0 ·· 9 0·10 (0·04–0·17) 0 ·· 0 ·· 9 0·10 (0·04–0·17)
Other or unspecified 
Gram negatives
0 ·· 15 0·06 (0–0·20) 375 0·31 (0·28–0·33) 4 0·06 (0·01–0·13) 394 0·12 (0·02–0·25)
Other pathogens 0 ·· 0 ·· 11 0·01 (0–0·02) 0 ·· 11 0·01 (0–0·02)
The extracted culture data were baseline data except for an intervention study from Senegal,81 where blood culture data were extracted before and after the intervention. Neonatal bacteraemia or sepsis 
pathogens represent data pooled across four studies from central Africa, 17 studies from eastern Africa, 13 studies from southern Africa, and 37 studies from west Africa. Neonatal meningitis pathogens 
represent data pooled across two studies from central Africa, six studies from eastern Africa, five studies from southern Africa, and six studies from west Africa.
Table 2: Regional distribution of pathogens causing serious bacterial neonatal infections, 2008–18
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regional differences in pathogen distribution. In our 
review, S aureus was a more important cause of 
bacteraemia or sepsis over the same period (1980–2007), 
whereas group B streptococcus and S pneumoniae 
accounted for over a third of neonatal meningitis 
infections for which a pathogen could be isolated. Our 
results show that since 2008, S aureus has remained an 
important cause of bacteraemia and sepsis, especially in 
hospital settings, whereas group B streptococcus and 
S pneumoniae are important causes of neonatal 
meningitis with differences in pathogen distribution 
between and within regions. Group B streptococcus 
and S pneumoniae present specific opportunities for 
interventions, for example by maternal immunisation.141–143
Our results show sub-regional geographical variation 
in the distribution of specific bacterial pathogens 
between and within regions (table 2). One key finding 
was the higher number of studies from southern Africa 
reporting group B streptococcus infections compared 
with other regions, although the prevalence of infections 
did not differ significantly across regions. Most data are 
from South Africa and, as noted by other reviews of 
aetiology and antimicrobial data in sub-Saharan Africa,9,144 
a specific focus on group B streptococcus research in 
South Africa could have led to geographical publication 
bias. In spite of this potential bias, true geographical 
differences in disease epidemiology or regional 
differences in virulence and host susceptibility cannot be 
ruled out.141,145 Variability in group B streptococcus disease 
might also reflect differences in case ascertainment 
(especially among home births), before antibiotic 
treatment, blood culture or lumbar puncture practices, 
variability in laboratory capacity, and the quality of 
microbiological investigations.145 A South African study146 
reported significant variation in neonatal invasive 
group  B streptococcus disease incidence by province 
with differential access to health care, poor laboratory 
capacity, and varying diagnostic procedures.146 Because 
early-onset group B streptococcus infection usually 
occurs within the first 24 h of life, with most presenting 
within hours of being born,147 those born at home or with 
limited access to health care are missed because they die 
at home.148
Another notable finding was the difference in the 
prevalence of S aureus bacteraemia or sepsis between 
regions, which was significantly higher in west Africa 
compared to southern Africa. Most of the west African 
studies were from Nigeria where the prevalence of S aureus 
bacteraemia or sepsis differed substantially according to 
how data was collected and the level of health-care facility. 
Potential explanations for the higher prevalence of 
infection in retrospective studies than in prospective 
studies include variability in what is defined as clinically 
significant and missing data, be that from ineffective study 
design or reporting. The higher prevalence of S aureus 
bacteraemia or sepsis among studies from tertiary facilities 
could be explained by the fact that these facilities receive 
patients from a wider geographical area, usually the sickest 
infants who might have already received care from one or 
more referral facilities and acquired pathogens from the 
hospital environment. S aureus is an important cause of 
neonatal hospital-acquired infections,149,150 and nosocomial 
outbreaks can go unrecognised.
Klebsiella spp and E coli normally colonise the maternal 
genital tract and can cause early-onset neonatal 
infections.151 However, multidrug-resistant ESBL-
producing organisms observed in several studies are 
usually acquired from contaminated hospital environ-
ments,152 with increased risk of mortality, especially 
among preterm babies.153 In Mali, typing of ESBL 
Enterobacteriaceae among bacteraemic children and 
adults from two referral hospitals showed a high rate of 
cross transmission between patients and the spread of 
strains from one hospital to another due to patient 
transfers.154 This finding underlines the crucial need for 
Figure 4: Forest plot of neonatal bacteraemia and meningitis, 2008–18
A summary estimate and 95% CI of the prevalence of pathogens causing invasive neonatal infection across regions 
in sub-Saharan Africa from studies published between 2008 and 2018: (A) Gram-positive and (B) Gram-negative 
causes of neonatal bacteraemia or sepsis; (C) Gram-positive and (D) Gram-negative causes of neonatal meningitis. 
Weights are from random effects analysis. ES=estimate (proportion). I² and p values are measures for 
heterogeneity between the studies.
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Central Africa
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Overall
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 6·65
 30·76
 34·07
 28·53
 100·00
0 0·5 0·75 1·00·25
D
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Central Africa East Africa Southern Africa West Africa All sub-regions
Number 
of 
isolates*
Resistance 
(95% CI)
Number 
of 
isolates*
Resistance 
(95% CI)
Number 
of 
isolates*
Resistance 
(95% CI)
Number 
of 
isolates*
Resistance 
(95% CI)
Number 
of 
isolates*
Resistance 
(95% CI)
Staphylococcus aureus
Cloxacillin36,79,84,93,97,98,123,124,
127
ND ·· 39 52% 
(36–68)
ND ·· 227 41% 
(8–79)
266 40% 
(8–79)
Oxacillin63,86,88,106,113,135 ND ·· 82 ·· 11 ·· 23 ·· 116 ··
Gentamicin36,63,79,84,88,93,97, 
98,106,111,113,118,123,124,127,135
ND ·· 119 21%  
(2–47)
8 63% 
(24–95)
279 26% 
(11–44)
406 27% 
(14–41)
Meticillin24,86,126,112,118,121,127, 
137
ND ·· 120 35% 
(13–62)
140 73% 
(57–86)
13 31% 
(13–58)
273 50% 
(30–70)
Cefoxitin36,88,113 ND ·· 49 27% 
(16–40)
ND ·· 35 14% 
(3–28)
84 16% 
(3–37)
Ciprofloxacin36,79,86,88,97,106, 
112,113,123
ND ·· 98 26% 
(9–47)
3 0 
(0–56)
172 13% 
(3–27)
273 16% 
(6–27)
Vancomycin63,86,88,112,126 ND ·· 50 0 
(0–12)
5 0 
(0–43)
23 35% 
(19–55)
78 5% 
(0–24)
Klebsiella spp
Gentamicin63,74,79,84,86,88,91,97, 
98,106,113,118,123–127,132,135
28 86% 
(70–97)
150 71% 
(33–97)
188 83% 
(57–99)
211 47% 
(26–69)
577 66% 
(47–83)
Cefotaxime36,63,86,88,91,98,106, 
125,132,135
28 98% 
(87–100)
56 52% 
(38–66)
176 89% 
(57–100)
49 54% 
(11–93)
309 78% 
(55–95)
Ceftazidime36,74,86,88,91,97,98, 
106,113,127,132
12 92% 
(65–99)
69 36% 
(25–48)
130 96% 
(92–99)
139 44% 
(11–80)
350 58% 
(28–86)
Ceftriaxone36,74,79,84,86,88,97,98, 
106,112,113,118,124,127
ND ·· 160 53% 
(34–71)
51 94% 
(84–98)
186 38% 
(13–66)
397 49% 
(28–71)
Ciprofloxacin36,63,79,86,91,97,106, 
112,113,118,123,135
12 92% 
(65–99)
144 14% 
(3–30)
98 58% 
(48–68)
135 26% 
(1–66)
389 30% 
(12–53)
Amikacin63,126,113,124,125,132,135 16 19%  
(7–43)
47 5% 
(0–15)
110 21% 
(8–38)
ND ·· 173 14% 
(7–23)
Carbapenem†63,86,88,91,106,125, 
126,132
28 11%  
(1–26)
56 0 
(0–6)
154 3% 
(0–11)
24 17% 
(1–10)
238 4% 
(1–10)
Piperacillin 
tazobactam63,125,126,132,135
16 44% 
(23–67)
5 0 
(0–43)
103 44% 
(22–67)
ND ·· 124 37% 
(19–57)
Escherichia coli
Ampicillin36,63,74,79,84,86,88,98,106, 
112,118,124,125,127, 132,135
4 100% 
(51–100)
66 93% 
(75–100)
28 84% 
(67–97)
51 78% 
(55–96)
149 89% 
(77–97)
Amoxycillin36,63,79,84,86,88,91,97, 
98,113,118,123,125
6 72% 
(24–100)
46 52% 
(13–90)
9 19% 
(0–57)
94 39% 
(11–71)
155 45% 
(24–66)
Cefotaxime36,63,86,91,98,106,125,
132,135
6 55% 
(10–96)
24 44% 
(21–68)
29 34% 
(12–69)
15 39% 
(12–69)
74 37% 
(12–66)
Ceftazidime36,74,86,88,91,97,98,106, 
113,123,127,132
2 100% 
(34–100)
34 33% 
(18–51)
19 68% 
(43–88)
63 41% 
(10–76)
118 48% 
(26–72)
Ceftriaxone74,79,84,86,88,97,98,106, 
112,113,124,127
ND ·· 64 40% 
(18–63)
5 100% 
(57–100)
64 24% 
(4–50)
133 38% 
(19–58)
Ciprofloxacin36,63,79,86,88,97,106, 
112,123,135
ND ·· 40 4% 
(0–16)
8 64% 
(24–96)
52 13% 
(0–34)
100 14% 
(3–30)
Gentamicin36,63,74,79,84,86,88,91, 
97,98,106,113,118,123–127,132,135
6 26%  
(0–74)
60 43% 
(13–75)
29 48% 
(9–88)
98 52% 
(13–90)
193 47% 
(25–69)
Amikacin63,124–126,132,135 4 0  
(0–49)
16 0 
(0–7)
23 8% 
(0–34)
ND ·· 43 1% 
(0–11)
Carbapenem†63,86,88,91,106,125, 
126,132
6 0  
(0–30)
24 0 
(0–13)
21 1% 
(0–28)
8 0 
(0–32)
59 0 
(0–5)
Piperacillin 
tazobactam63,125,132,135
4 25%  
(5–70)
1 0 
(0–79)
18 9% 
(0–30)
ND ·· 23 7% 
(0–27)
ND=no data. *Cumulative number of isolates tested across cited studies with susceptibilities reported; not all studies tested susceptibilities to all listed antibiotics. 
†Includes imipenem and meropenem.
Table 3: Antimicrobial resistance in organisms causing serious bacterial neonatal infections across 29 studies from sub-Saharan Africa, 2008–18
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improved infection prevention measures particularly in 
congested neonatal units with high antimicrobial 
exposure and poor infection control.14,81,150,155
In our study, we identified a high prevalence of 
resistance to recommended empirical therapies, in 
keeping with reports from older paediatric and adult 
populations in Africa.9,156,157 Similar high resistance rates 
have been reported among South Asian neonates, 
including in India where an excess of 80 000 neonates die 
each year from resistance-attributable neonatal sepsis.8,158 
Alternative therapeutic options such as fluoroquinolones, 
carbapenems, and piperacillin with tazobactam are 
scarce, expensive, and inappropriate for use in 
community settings, and are therefore considered 
antibiotics of last resort.11,159 We have found low to 
moderate rates of resistance to these antimicrobials in 
studies included in this review. Our high reported rates 
of MRSA are in keeping with a previous review MRSA in 
Africa,160 and suggest that treatment for suspected or 
confirmed S aureus infection must rely on second-line 
drugs such as vancomycin, which are expensive and can 
have severe side-effects.161 Our finding of reduced 
susceptibility to amoxicillin among S aureus is particularly 
worrisome given that it is the only WHO-recommended 
oral antibiotic for outpatient treatment of possible 
serious bacterial infection in infants whose families do 
not accept or cannot access hospital-based care.162 The 
emergence of resistance to this simple option is likely to 
result in more deaths.
Our findings have some limitations. First, although 
our search generated many results, some potentially 
eligible studies were excluded for not providing separate 
neonatal aetiological data. Included studies were mostly 
from west Africa, with a third of studies from Nigeria, 
and there was little or no data for other countries with 
similar neonatal mortality, particularly in conflict 
and post-conflict countries. Second, there was high 
heterogeneity between studies, although this was 
expected because of the differences in case ascertainment, 
microbiological methods, and data collection methods 
between the included studies. Third, because most of the 
studies reported collection of only one sample, it was 
difficult to identify instances that a specific organism 
should be considered a contaminant or not, particularly 
in the case of CoNS which we excluded from our review. 
It is therefore possible that some real pathogens were 
missed, or some contaminants were included.
Nevertheless, these data provide useful insights into the 
pathogens associated with neonatal invasive bacterial 
infection in sub-Saharan Africa and the status of AMR. 
Interventions that focus on hospital-based care around the 
time of birth could prevent millions of neonatal and 
maternal deaths, stillbirths, and disability.163 With poor 
quality care, dangers of infection transmission and AMR 
threaten the gains of neonatal survival. Reducing the 
burden of neonatal infection mortality and morbidity 
requires a multipronged approach. Infection prevention 
and surveillance of hospital-acquired infections is crucial 
together with expanded and improved clinical microbiology 
services for pathogen detection and optimum treatment. 
Tailored local antimicrobial guidelines, implementation 
of antimicrobial stewardship policies, and effective 
antimicrobial surveillance are necessary strategies to tackle 
AMR.9 Innovative point-of-care diagnostics would be 
transformative. Although there is potential for maternal 
vaccines against group B streptococcus and S pneumoniae, 
the value proposition of new vaccines should be based on 
sound data. Differences in geographical distribution of 
specific bacterial serotypes needs to be determined to 
guide optimal selection of vaccine targets.
Despite marked increases in facility births, almost half 
of the 36 million annual births in sub-Saharan Africa still 
occur at home, and many neonates never receive 
treatment when sick.6 The scarcity of aetiology and AMR 
data from community-based studies poses a crucial gap in 
the knowledge of pathogens causing infections in babies 
born and dying at home. The Aetiology of Neonatal 
Infections in South Asia (ANISA), an observational cohort 
study, identified atypical bacteria and respiratory syncytial 
virus infection as the predominant causes of community-
acquired serious infections among infants in that region.148 
No such study has yet been completed in Africa where 
rates of infection and pathogens seen are likely to be 
different from those seen in Asia.
Our findings also underscore the current research waste 
for reported data on neonatal infection aetiology, 
antimicrobial sensitivity, and outcomes.20 Application of 
the STROBE-NI checklist could improve scientific 
reporting, increase comparability, and reduce waste of data 
in high-burden regions.20 However, although unified 
reporting standards and more studies are needed, the 
burden of neonatal infections will only be reduced if these 
data are available and used locally by public health leaders 
and programme managers, and implemented within local 
health-care systems, while respecting local contexts.13
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